Compare Biogen Inc (BIIB) vs GE Aerospace (GE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs GE Aerospace — how do they compare? Biogen Inc trades at $191.1 (market cap $28.34B), while GE Aerospace trades at $355.33 (market cap $369.06B). The key difference: GE Aerospace is far larger — about 13× Biogen Inc's market cap, and GE Aerospace pays a 0.53% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | GE | |
|---|---|---|
Market Cap | $28.34B | $369.06B |
Sector | Health | Industrials |
52-Week High | $216.63 | $378.68 |
52-Week Low | $122.68 | $259.00 |
Enterprise Value | $30.62B | $378.36B |
Dividend Yield | — | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
GE trades at $353.73, down 1.54% today, with a bullish technical signal from moving averages and oversold RSI levels. The company reported strong Q1 2026 earnings of $1.86 per share, beating estimates, supported by robust aerospace demand and defense contract wins. Revenue grew to $45.86 billion in 2025, with net income margins improving to 17.86%. Analysts maintain a bullish consensus with a $397 price target, citing order growth and backlog strength.
Outlook remains positive due to aerospace momentum and strategic investments, but high valuation ratios (P/E 43.9) and debt levels pose risks. The stock offers upside to consensus targets, though investors should monitor execution on growth initiatives and macroeconomic pressures on defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
